Various potential biomarkers have been found in colon adenocarcinoma (COAD) patients receiving immunotherapy, such as microsatellite instability (MSI), programmed cell death-ligand 1 (PD-L1) expression, tumor mutation burden (TMB) and BRAF and KRAS gene mutation status (6). This evidence concerns the gene CD274 and neoplasm.